May 7, 2019 06:08 AM EDTUpdated May 8, 10:24 AM

Top MedImmune research exec joins the team now running Immunocore in wake of an R&D restructuring at AstraZeneca

John Carroll

Editor & Founder

Bahija Jallal is being reunited with another one of her former colleagues at AstraZeneca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Top MedImmune research exec joins the team now running Immunocore in wake of an R&D restructuring at AstraZeneca

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company

Top Med­Im­mune re­search ex­ec joins the team now run­ning Im­muno­core in wake of an R&D re­struc­tur­ing at As­traZeneca

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

Up­dat­ed: Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

Top MedImmune research exec joins the team now running Immunocore in wake of an R&D restructuring at AstraZeneca

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company